This story is re-published as a summary and extract of a story on Dr Mercola’s website, written by Dr Mercola, published March 9, 2020.
The number of deaths due to COVID-19 are still on the rise worldwide. By far, the majority of these deaths so far are in the Hubei Province in and around Wuhan City, according to Dr Mercola from
COVID-19 — An Escaped Bioweapon?
According to bioweapons expert Francis Boyle, whom I recently interviewed on this topic, the evidence suggests COVID-19 is a weaponized coronavirus originating from the Biosafety Level 4 facility in Wuhan City. It’s the first BSL-4 facility in China, and was set up specifically to research coronavirus and SARS.
He describes COVID-19 as a chimera consisting of SARS (an already weaponized coronavirus), HIV genetic material and influenza virus, designed with so-called “gain of function” properties that allow it to spread a greater distance than normal.
COVID-19 can travel 6 to 7 feet through the air, and some reports suggest the virus can shed that distance from contaminated human feces as well. Others have suggested COVID-19 may involve Prevotella, a bacterium known to cause respiratory tract infections, including pneumonia, and that this may explain some of the observed symptoms and how it can spread through feces.
The Bacteriophage Hypothesis
Bacteriophages — viruses that infect and reproduce inside bacteria, like a parasite — have been implicated “in the progression and maintenance of at least some pathologies, including those associated with protein misfolding,” according to one 2018 paper, which further notes:8
“Here, for the first time, we propose the concept of bacteriophages as human pathogens. We suggest that bacterial viruses have different ways to directly and indirectly interact with eukaryotic cells and proteins, leading to human diseases.”
In a February 2020 paper,9 Sandeep Chakraborty, a bioinformatics core member at UC Davis,10 notes that Prevotella “is present (sometimes in huge amounts) in patients from two studies in China and one in Hong Kong.”
He goes on to cite RNA sequencing data11 from Wuhan, China, published January 25, 2020, showing “millions of reads of Prevotella proteins” amid a few thousand COVID-19 viruses. Yet the researchers make no mention of the Prevotella in their paper. Prevotella bacteria was also found in six COVID-19 patients from the same family in Hong Kong.12
“These are the three studies I could find,” Chakraborty writes.13 “But the clinching evidence is the presence of the same integration point of nCov and Prevotella in Study 1 and Study 2.
Moreover, detection of the nCoV can be made very spec[f]ic by looking for a 500bp in the spike protein, which would be a good candidate for vaccine development, protein-inhibition and diagnosis (which was non-specific for SARS in many cases, including the CDC test). And, since this is now DNA, the standard detection tests using RT-PCR, which looks for RNA is having large false negatives.”
While this connection needs further verification and validation, it’s an interesting finding that could be significant if true. From a treatment standpoint, it could indicate that antibiotic drugs might be useful, and for prevention, probiotics, prebiotics and/or sporebiotics might play an important role.
There’s still a lot we don’t know about COVID-19, and if it did escape from Wuhan City’s BSL-4 facility, they’re not giving out any details about it that might help health care workers figure out an effective treatment plan.
While vitamin C treatment is one avenue under investigation, and wearing medical-grade face masks is the route many have taken to avoid infection, taking steps to strengthen your immune function is likely one of your most important prevention strategies. I review several of these strategies below.
Vitamin C Treatment for Coronavirus Under Investigation
February 4, 2020, researchers at Zhongnan Hospital in China announced they will investigate the effectiveness of vitamin C infusion for the treatment of severe COVID-19 infected pneumonia.14
Many of the deaths associated with this viral pneumonia appear to be due to septic shock,15 and studies suggest high-dose vitamin C infusions can improve outcomes in cases of sepsis16 and respiratory infections.17 As noted in the Zhongnan Hospital’s study description:18
“Viral pneumonia is a dangerous condition with a poor clinical prognosis … Vitamin C, also known as ascorbic acid, has antioxidant properties. When sepsis happens, the cytokine surge caused by sepsis is activated, and neutrophils in the lungs accumulate in the lungs, destroying alveolar capillaries.
Early clinical studies have shown that vitamin C can effectively prevent this process. In addition, vitamin C can help to eliminate alveolar fluid by preventing the activation and accumulation of neutrophils, and reducing alveolar epithelial water channel damage.
At the same time, vitamin C can prevent the formation of neutrophil extracellular traps, which is a biological event of vascular injury caused by neutrophil activation.”
The researchers intend to treat patients with 24 grams of IV vitamin C per day for seven days at a speed of 7 milliliters per hour. The placebo group will receive an IV of normal saline.
The primary outcome measure will be the number of days without ventilation support during 28 days of hospitalization. Secondary outcome measures will include mortality, ICU length of stay, the rate of CPR required, vasopressor use, respiratory function, sepsis-related organ failure and more.
Dr. Marik’s Sepsis Treatment Protocol may be a Good Option
Time will tell what the outcome of that Zhongnan Hospital study will be. Chances are vitamin C will impart some benefit, although Dr. Paul Marik’s sepsis treatment protocol might be an even better option.
One initial retrospective before-after clinical study19,20 showed giving patients 200 mg of thiamine every 12 hours, 1,500 mg of ascorbic acid (vitamin C) every six hours, and 50 mg of hydrocortisone every six hours for two days reduced sepsis mortality from 40% to 8.5%.
Research,21,22 published online January 9, 2020, found Marik’s intravenous sepsis protocol lowered mortality in pediatric patients as well. The study was performed at Ann & Robert H. Lurie Children’s Hospital of Chicago, and as noted by Science Daily,23 the preliminary data from this study “supports the promising outcomes seen in adults.”
Between January 2014 and February 2019, 557 pediatric patients with septic shock met the criteria for inclusion in the study. Forty-three received Marik’s vitamin C-B1-hydrocortisone protocol, 181 received hydrocortisone-only therapy, and 333 received neither of these treatments. The 43 patients receiving the vitamin C treatment were matched based on clinical status with 43 untreated controls and 43 hydrocortisone-only patients.
At the 30-day mark, controls and the hydrocortisone-only groups had a mortality rate of 28% while the treatment group had a mortality rate of just 9%. At 90 days, 35% of the controls and 33% of those receiving hydrocortisone-only had died, compared to just 14% of the treatment group.24
– Sources and References